Targeted methods for molecular characterization of EGFR mutational profile in lung cancer Moroccan cohort

Kaanane, Houda; Attar, H. El; Louahabi, A.; Casa, Igot; Berradi, Hind; Idrissi, Hind Hassani; Khyatti, Meriem; Nadifi, Sellama

doi:10.1016/j.gene.2019.04.044

Cited by 7 publications

(16 citation statements)

References 49 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The good sensitivity and specificity of the rapid detection of EGFR mutations using the Idylla TM system were previously reported in other publications on lung cancer, as well as on other cancers such as melanoma and colorectal cancer [ 17 ]. Similarly, as detailed in the introduction, the concordance of EGFR genotyping has already been reported between the Idylla TM system and NGS [ 12 , 13 , 14 , 15 , 16 , 17 , 18 , 19 , 20 , 21 , 22 ] or other techniques [ 23 , 24 , 25 , 26 , 27 , 28 , 29 , 30 ]. In our center, we chose to introduce the Idylla TM system rather than another rapid assay, because our main objective was to reduce, at maximum, the result of the EGFR genotyping for clinicians and to reduce the need of DNA extraction being performed daily, not allowing this objective to be achieved.…”

Section: Discussionmentioning

confidence: 60%

“…In our center, we chose to introduce the Idylla TM system rather than another rapid assay, because our main objective was to reduce, at maximum, the result of the EGFR genotyping for clinicians and to reduce the need of DNA extraction being performed daily, not allowing this objective to be achieved. In fact, the Idylla TM system is one of the rare solutions avoiding DNA extraction and allowing reliable EGFR genotyping directly from FFPE sample slides [ 20 , 25 , 33 , 34 , 35 ] in all patients with advanced NSCLC, mainly adenocarcinomas and squamous cell carcinomas in never-smokers, as in patients with stage IB to IIIA resected EGFR mutation-positive NSCLC [ 8 ]. However, the Idylla TM system has several limitations.…”

Section: Discussionmentioning

confidence: 99%

“…Previous studies have already reported the high concordance (from 94% to 100%) between the Idylla TM system and other methods routinely used for EGFR mutation detection from formalin-fixed paraffin-embedded (FFPE) tissue of human lung cancer (NGS: [ 12 , 13 , 14 , 15 , 16 , 17 , 18 , 19 , 20 , 21 , 22 ]; pyrosequencing: [ 23 ]; Therascreen ® EGFR RGQ PCR: [ 24 ]; droplet digital PCR: [ 22 ]; ARMS PCR: [ 25 ]; fragment PCR: [ 26 , 27 ]; multiplex PCR: [ 28 ]; real-time PCR (cobas ® EGFR Mutation Test): [ 29 ]; Sanger sequencing: [ 29 , 30 ]), usually through a retrospective and monocenter study, although sometimes prospective [ 13 , 18 , 28 , 29 , 31 ] and rarely multicentric [ 15 ]. Previous studies have thus evaluated the sensitivity, concordance, and reproducibility between NGS and the alternative technical approaches of EGFR genotyping, but whether the early genotyping of EGFR can initiate more quickly the treatment of patients with NSCLC is not clearly answered in the literature.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Contribution of the IdyllaTM System to Improving the Therapeutic Care of Patients with NSCLC through Early Screening of EGFR Mutations

et al. 2021

View full text Add to dashboard Cite

Epidermal growth factor receptor (EGFR) genotyping, a critical examen for the treatment decisions of patients with non-small cell lung cancer (NSCLC), is commonly assayed by next-generation sequencing (NGS), but this global approach takes time. To determine whether rapid EGFR genotyping tests by the IdyllaTM system guides earlier therapy decisions, EGFR mutations were assayed by both the IdyllaTM system and NGS in 223 patients with NSCLC in a bicentric prospective study. IdyllaTM demonstrated agreement with the NGS method in 187/194 cases (96.4%) and recovered 20 of the 26 (77%) EGFR mutations detected using NGS. Regarding the seven missed EGFR mutations, five were not detected by the IdyllaTM system, one was assayed in a sample with insufficient tumoral cells, and the last was in a sample not validated by the IdyllaTM system (a bone metastasis). IdyllaTM did not detect any false positives. The average time between EGFR genotyping results from IdyllaTM and the NGS method was 9.2 ± 2.2 working days (wd) (12.6 ± 4.0 calendar days (cd)). Subsequently, based on the IdyllaTM method, the timeframe from tumor sampling to the initiation of EGFR-TKI was 7.7 ± 1.2 wd (11.4 ± 3.1 cd), while it was 20.3 ± 6.7 wd (27.2 ± 8.3 cd) with the NGS method (p < 0.001). We thus demonstrated here that the IdyllaTM system contributes to improving the therapeutic care of patients with NSCLC by the early screening of EGFR mutations.

show abstract

Section: Discussionmentioning

confidence: 60%

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Contribution of the IdyllaTM System to Improving the Therapeutic Care of Patients with NSCLC through Early Screening of EGFR Mutations

et al. 2021

View full text Add to dashboard Cite

show abstract

“…[22] Data from Egypt, Tunisia, and Morocco indicated higher frequency of P53 genetic mutation in lung cancer among North Africans though EGFR and MMP-3 mutations share similarities to their neighboring European countries. [39][40][41][42][43][44][45] However, genetic studies from North Africa cannot be extrapolated to all Africans since the people of North Africa are a genetically diverse, complex and heterogeneous population consisting of an admixture of Middle East Arabs, sub-Saharan Africans (SSAs), European, and autochthonous North Africans. [46,47] Cigarette smoking is one of the most studied non-genetic or modifiable lung cancer risk factors in Africans.…”

Section: Risk Factors and Prevalence In Africamentioning

confidence: 99%

Management of lung cancer in Africa: Underdiagnosis and poor access to treatment – A close look at Nigeria and West African Sub-region

Okonta

Echieh

Abubakar

et al. 2021

JPATS

View full text Add to dashboard Cite

Lung cancer is of public health importance and imposes a great deal of socioeconomic and disease burden on the West African subregion and Nigeria in particular. It is one of the most common cancers worldwide and accounts for 11.4% of all new cancers. In this review, we did not find any well-coordinated lung cancer registry in either Nigeria or any other West African country. For us to attain any meaningful level of the interventional plan to address any identifiable deficiencies in the treatment of lung cancer in the West African subregion, it is imperative that a specific regional lung cancer registry with a regular audit of the reporting, is set up. There is an urgent need for further studies on the local risk factors predisposing to lung cancer, especially in the younger age group. Finally, intense pressure must be mounted on the governments within West Africa to implement the 15% GDP allocation to the health budget as agreed in the WHO/Abuja Declaration and to speed up efforts towards universal health insurance.

show abstract

“…Original articles were identi ed from Jordan [19], Iran [20,21], Turkey [22][23][24][25][26], Bahrain [27], Iraq [29,30], Lebanon [31][32][33], Morocco [35][36][37], Tunisia [38][39][40], Egypt [41], and Algeria [42]. A multicenter prospective study from Levant (Lebanone, Syria, Palestine, Jordan, Iraq, and Egypt) [34] and a multisite retrospective study from Gulf region (Saudi Arabia, the United Arab Emirates and Qatar) were also identi ed and will part of our analysis [28].…”

Section: Introductionmentioning

confidence: 99%

Prevalence and Patterns of EGFR Mutations in Non-Small Cell Lung Cancer in the Middle East and North Africa: A Systematic Review

Boustany

Laraqui

Rhaffouli

et al. 2021

Preprint

View full text Add to dashboard Cite

To summarize current evidence and estimate the prevalence of epidermal growth factor receptor (EGFR) mutation frequency and its association with ethnicity and clinic-pathological features in non-small cell lung cancer (NSCLC) patients in the Middle East (ME) and North Africa (NA), a systematic literature review was undertaken. We conducted a literature search of original articles published in six databases (PubMed, Science Direct, Web of Science, Embase, Scopus, and Google scholar) from the time of inception until April 2021. Search terms included “lung cancer”, “NSCLC”, “EGFR mutation”, “Middle East”, “North Africa”, and specific country names belonging to the considered region. The included studies had to meet the following criteria: the study must relate to the role of the EGFR gene in NSCLC, analyze mutations in exon 18, 19, 20, and 21 or select exons of the EGFR gene, and provide sufficient information on the clinic-pathological characteristics of the included NSCLC patients. A total of 24 eligible studies were included [(66.6%) in the ME and (34.4%) in NA]. Overall, 6544 patients with NSCLC were analyzed for EGFR mutations [(55.1%) in the ME and (44.8%) in NA]. The overall prevalence of EGFR mutations was 17.9%. In the ME, the reported frequency was 17.3%, whereas in NA, the prevalence of EGFR mutations was 18.5%. The most frequently encountered mutations were the exon 19 deletions (45.2%) and exon 21 substitutions (30.9%). Exon 20 alterations were detected in 11.2%, of which, the T790M resistance mutation was the most prevalent (45.5%). Exon 18 mutations were reported in 3.8%. In the ME, 50.5% of NSCLC patients were positive for exon 19 deletions versus 48.3% in NA. Exon 21 mutations were slightly more commonly detected in the ME (36.3%) than NA (31.3%). There was 1.2% of patients that had concurrent EGFR mutations. Overall, EGFR mutations prevalence was higher in females, non-smokers, and patients with adenocarcinoma. Our systematic literature review concurs that EGFR mutation prevalence among MENA populations is slightly higher than that seen in NSCLC patients of Caucasian ethnicity but is lower than that identified in Asian NSCLC patients. The distribution of these mutations varies significantly throughout the MENA region.

show abstract

Targeted methods for molecular characterization of EGFR mutational profile in lung cancer Moroccan cohort

Cited by 7 publications

References 49 publications

Contribution of the IdyllaTM System to Improving the Therapeutic Care of Patients with NSCLC through Early Screening of EGFR Mutations

Contribution of the IdyllaTM System to Improving the Therapeutic Care of Patients with NSCLC through Early Screening of EGFR Mutations

Management of lung cancer in Africa: Underdiagnosis and poor access to treatment – A close look at Nigeria and West African Sub-region

Prevalence and Patterns of EGFR Mutations in Non-Small Cell Lung Cancer in the Middle East and North Africa: A Systematic Review

Contact Info

Product

Resources

About